Molecular Diagnosis and Risk Stratification of Sepsis (MARS)
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
This observational or N/A phase trial investigates Sepsis and is currently ongoing. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) leads this study, which shows 13 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Aug 2023 — Jul 2024 [monthly]
Unknown Status
-
Mar 2022 — Aug 2023 [monthly]
Unknown Status
-
Dec 2021 — Mar 2022 [monthly]
Unknown Status
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Jul 2018 — Nov 2020 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Jul 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Biocartis NV
- Center for Translational Molecular Medicine
- Check-Points
- Immunetrics
- Immunexpress
- Microbiome
- Philips Healthcare
- Radboud University Medical Center
- UMC Utrecht
For direct contact, visit the study record on ClinicalTrials.gov .